These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26063449)

  • 1. Edoxaban and amiodarone: interactions on multiple levels.
    Conen D
    Eur Heart J; 2015 Sep; 36(33):2210-1. PubMed ID: 26063449
    [No Abstract]   [Full Text] [Related]  

  • 2. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.
    Steffel J; Giugliano RP; Braunwald E; Murphy SA; Atar D; Heidbuchel H; Camm AJ; Antman EM; Ruff CT
    Eur Heart J; 2015 Sep; 36(33):2239-45. PubMed ID: 25971288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amiodarone in atrial fibrillation.
    Jolobe OM
    Postgrad Med J; 1999 Nov; 75(889):703. PubMed ID: 10621894
    [No Abstract]   [Full Text] [Related]  

  • 4. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
    Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation therapy. Optimal dosages and genotypes for edoxaban therapy.
    Huynh K
    Nat Rev Cardiol; 2015 May; 12(5):256. PubMed ID: 25824520
    [No Abstract]   [Full Text] [Related]  

  • 6. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
    Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin pharmacogenetics in the era of new oral anticoagulants.
    Wright GE
    Clin Genet; 2015 Aug; 88(2):135-6. PubMed ID: 25970639
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacogenomic testing and response to warfarin.
    Wu AH
    Lancet; 2015 Jun; 385(9984):2231-2. PubMed ID: 25769360
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
    Rost NS; Giugliano RP; Ruff CT; Murphy SA; Crompton AE; Norden AD; Silverman S; Singhal AB; Nicolau JC; SomaRaju B; Mercuri MF; Antman EM; Braunwald E;
    Stroke; 2016 Aug; 47(8):2075-82. PubMed ID: 27387994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
    Giugliano RP; Ruff CT; Wiviott SD; Nordio F; Murphy SA; Kappelhof JA; Shi M; Mercuri MF; Antman EM; Braunwald E
    Am J Med; 2016 Aug; 129(8):850-857.e2. PubMed ID: 26994510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
    Chen J; Zhuang X; Long M; Su C; Wang L
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2710-9. PubMed ID: 26324517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.
    Khoo CW; Lip GY
    Expert Opin Pharmacother; 2010 Mar; 11(4):685-7. PubMed ID: 20105114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
    Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
    Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?
    Plitt A; Giugliano RP
    Future Cardiol; 2014 Mar; 10(2):153-5. PubMed ID: 24762238
    [No Abstract]   [Full Text] [Related]  

  • 17. [Update on current care guidelines: atrial fibrillation].
    Käypä hoito -suosituksen päivitystiivistelmä
    Duodecim; 2012; 128(4):374-6. PubMed ID: 22448550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edoxaban: a review in nonvalvular atrial fibrillation.
    McCormack PL
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):351-61. PubMed ID: 26369340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The ENGAGE AF-TIMI 48 study].
    Rubboli A; Colonna P
    G Ital Cardiol (Rome); 2015 Sep; 16(9):457-61. PubMed ID: 26418383
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany.
    Krejczy M; Harenberg J; Wehling M; Obermann K; Lip GY
    Biomed Res Int; 2015; 2015():876923. PubMed ID: 25853142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.